Nicht aus der Schweiz? Besuchen Sie lehmanns.de

Managing Metastatic Prostate Cancer In Your Urological Oncology Practice

K.C Balaji (Herausgeber)

Buch | Hardcover
XIII, 280 Seiten
2016 | 1st ed. 2016
Springer International Publishing (Verlag)
978-3-319-31339-9 (ISBN)

Lese- und Medienproben

Managing Metastatic Prostate Cancer In Your Urological Oncology Practice -
CHF 104,80 inkl. MwSt
  • Versand in 10-15 Tagen
  • Versandkostenfrei
  • Auch auf Rechnung
  • Artikel merken
This text provides a comprehensive review of pathophysiology, molecular and cell biology aspects of CRPC, discusses all major clinical trials that have led to approval of 6 new drugs since 2004, explores the role of bone preservation strategies, in depth analysis of combination and sequencing strategies, outlines upcoming novel drugs and trends in research, and stresses the role of palliative care in this incurable disease. Managing Metastatic Prostate Cancer in Your Urological Oncology Practice will serve as a very useful resource for physicians and researchers dealing with, and interested in prostate cancer. It provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts. All chapters are written by experts in their fields and will include the most up to date scientific and clinical information.

K.C. Balaji, MD Chief of Urology, W.G. (Bill) Hefner VA Medical Center, Salisbury, North Carolina Professor of Urology and Cancer Biology, Wake Forest University School of Medicine, Winston Salem, North Carolina Department of Urology, Cancer Biology, Institute of Regenerative Medicine Wake Forest University School of Medicine, W.G. (Bill) Hefner VA Medical Center

Introduction.- Pathophysiology of Castration-Resistant Prostate Cancer.- Androgen Receptor Signaling in Castration Resistant Prostate Cancer.- Non-Androgen Signaling Pathways in Castration-Resistant Prostate Cancer.- Predictive Models in Castration Resistant Prostate Cancer.- Docetaxel in Advanced and Castration Resistant Prostate Cancer.- Combination Treatment Strategies with Docetaxel in Patients with Metastatic Prostate.- Cancer Vaccines in Castration Resistant Prostate Cancer - An evolution in design.- Abiraterone for the treatment of mCRPC.- Enzalutamide in Metastatic Castration Resistant Prostate Cancer.- Radium-223 in Metastatic Castrate Resistant Prostate Cancer.- Cabazitaxel for the Treatment of Prostate Cancer.- Sequencing Therapies in Metastatic Castration Resistant Prostate Cancer.- Bone Preservation Strategies for Men on Androgen Deprivation Therapy.- Novel Therapies in Castration-Resistant Prostate Cancer.

Erscheinungsdatum
Zusatzinfo XIII, 280 p.
Verlagsort Cham
Sprache englisch
Maße 155 x 235 mm
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Onkologie
Medizin / Pharmazie Medizinische Fachgebiete Urologie
Schlagworte Abiraterone Acetate • Cabazitaxel • castration resistant prostate cancer • Docetaxol Chemotherapy • Enzalutamide • Medicine • Oncology • Urology
ISBN-10 3-319-31339-8 / 3319313398
ISBN-13 978-3-319-31339-9 / 9783319313399
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich

von Hannes Leischner

Buch | Softcover (2023)
Urban & Fischer in Elsevier (Verlag)
CHF 37,80
Resilienz innovativ stärken : ein Praxishandbuch

von Christa Diegelmann; Margarete Isermann; Tanja Zimmermann

Buch | Softcover (2023)
Kohlhammer (Verlag)
CHF 49,95